Shire’s Vyvanse Ruling May Support Bid Above GBP55/Shr: Barclays
2014-06-25 10:51:47.976 GMT
By Allison Connolly
June 25 (Bloomberg) -- U.S. ruling on Vyvanse patent
infringement lawsuit is positive, supports Shire’s own
valuation, Barclays says in note.
* Barclays (overweight): AbbVie could increase bid above
GBP55/shr vs previous GBP46.26/shr based on tax inversion
benefit, assurance on Vyvanse patent strength
* Says drug accounts for ~30% of co. earnings so patent
uncertainty is significant sentiment driver
* NOTE: Earlier, Shire Says U.S. Court Grants Summary Judgment
Motion on Vyvanse
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
2014-06-25 10:51:47.976 GMT
By Allison Connolly
June 25 (Bloomberg) -- U.S. ruling on Vyvanse patent
infringement lawsuit is positive, supports Shire’s own
valuation, Barclays says in note.
* Barclays (overweight): AbbVie could increase bid above
GBP55/shr vs previous GBP46.26/shr based on tax inversion
benefit, assurance on Vyvanse patent strength
* Says drug accounts for ~30% of co. earnings so patent
uncertainty is significant sentiment driver
* NOTE: Earlier, Shire Says U.S. Court Grants Summary Judgment
Motion on Vyvanse
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net